Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

05.02.2020 | short review | Ausgabe 1/2020 Open Access

memo - Magazine of European Medical Oncology 1/2020

AML—is it time to drive a CAR(-T)?

memo - Magazine of European Medical Oncology > Ausgabe 1/2020
Dr. Jakob D. Rudzki, Dominik Wolf
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
CAR transgenic T cells have led to impressive clinical results in treating patients with relapsed and refractory B cell leukemia and lymphoma [ 13]. To date, increasing numbers of publications are reporting trials using CAR transgenic T cells in B cell-derived malignancies. Most of these strategies are directed against CD19 as target antigen, a B cell-lineage antigen expressed on the surface of normal as well as on many malignant B cells (e.g. B‑NHL and acute lymphoblastic leukemia). Long-term follow-up of up data now reaching 3 years revealed convincing results in chemotherapy refractory or relapsed DLBCL patients [ 24].
Similar to CD19 targeting also additional or alternative target antigens, such as CD20 are approached as target for CAR T cell therapy in B cell malignancies. Early studies illustrate modest efficacy without significant toxicities suggesting that CD20 targeting may possibly be an additional target on B‑NHL [ 5]. Recently, a phase IIa clinical trial reported an objective response rate (ORR) of 82% (complete remission [CR] of 6/11 and partial remission [PR] of 3/11) with well-tolerated toxicity [ 6]. These early promising findings suggest that CD20 targeting may represent an interesting additional or alternative target, for example, by applying dual or bispecific CAR-T cells targeting both CD19 and CD20.
AML is the most common acute leukemia in adults. Even though many drugs were approved during the last 2 years, the disease is still characterized by a very poor prognosis reflected by only a minority of patients achieving long-term survival. The overall cure rate in AML patients below 60 years is about 35–40% and drops to 5–15% for patients older than 60 years. Patients who never reach remission or suffer from early relapse within 6 months of CR (complete remission) are less likely to respond to any other salvage treatment [ 7]. Thus, high primary treatment failure and frequent AML relapse remains a significant problem in the clinical management of AML. Since the availability of hypomethylating agents (HMA) and more recently also of venetoclax, AML therapy in patients unfit for intensive induction has improved, even though it remains a palliative setting. Thus, apart from AML M3 and ELN good risk AML (in both of which consolidation is drug-based), allogeneic stem cell transplantation has been the most frequently used consolidation strategy in intermediate- or high-risk AML patients fit for transplant and having a suitable donor. However, the latter consolidation is still characterized by high relapse rates as well as significant treatment-related mortality, which underscores the high medical need to improve AML management. Cell-based treatment strategies using CAR-T cells thus represents an appealing approach to be tested also in AML patients, but the limited availability of appropriate targets still represents a major obstacle for a broader success of this cell-based treatment concept in AML.

Effectiveness of CAR-T cell treatment depends on the choice of the optimal target

The extracellular domain of the transgenic CAR construct recognizes a predefined target on the respective leukemia/tumor cells. Upon target binding, the chimeric construct containing intracellular co-stimulatory signaling domains, such as 4‑1BB or CD28 connected to CD3zeta [ 8, 9], potently activate the CAR-T cell leading to target cell killing and stimulation of other immune cells in the adjacent tumor microenvironment.
Identifying the optimal target in the case of AML still remains a big challenge. Owing to the positive results of anti CD33-directed therapy with the immunotoxin gemtuzumab ozogamizin, CD33-directed therapies represent a promising tool, particularly because almost 90% of AMLs express CD33 [ 10]. Moreover, 70% are marked by being double expressors of CD33 and CD123 and only 10% express CD123 without concomitant CD33 on their surface [ 11] making both CD33 together with CD123 interesting targets for CAR-T in AML. However, based on expression of these markers also on non-leukemic hematopoietic stem cells, dual targeting [ 12, 13] of CD33 together with CD123 not only eradicated the leukemia, but also caused long-term myeloablation that required subsequent HSCT (hematologic stem cell transplantation) to allow for hematopoietic recovery. Several other target antigens, like CD174 (Lewis Y antigen), CD44v6, CLL‑1 (CLEC12A), CD7, folate receptor beta (FRbeta), and CD135 (FLT‑3 receptor) were subsequently defined allowing a more selective targeting of AML. Unfortunately, none of the mentioned target molecules is exclusively expressed on AML blasts as most of them are also detectable on different hematologic progenitor cells or other healthy tissues (keratinocytes, neurons), thereby limiting the clinical translation [ 12].
In addition, another hurdle of CAR-T cell therapy is the clonal heterogeneity of the AML. In this respect, dual targeting, as already tested in B‑ALL CAR-T trials, may help to overcome this issue, but still elimination of healthy stem cells remains an issue [ 6, 13]. This may also help to prevent treatment failure mediated by antigen loss, a phenomenon well described for CD19-expressing ALL. Another resistance mechanism is a structural change of the target molecule induced by selection of mutated subclones [ 14]. Similar to antigen loss, this escape mechanism can at least be overcome by dual targeting concepts.
The clue is to find well expressed antigen sets represented on AML blasts but excluding healthy hematopoietic cells and non-hematologic tissue. Perna et al. integrated large transcriptomics and proteomics datasets from malignant and normal tissue and developed an algorithm to identify potential targets expressed on leukemic stem cells. Their findings identified potential targets expressed in leukemia cells but not in normal CD34 +CD38 - hematopoietic cells, T cells or vital tissues which therefore could serve as novel promising CAR-T targets [ 15].

Clinical status of CAR-T therapy in AML

The first clinical CAR-T trial in AML was developed based on the observation that the Lewis Y (LeY) oligosaccharide is overexpressed on many epithelial cancers as well as hematologic malignancies (including AML) with limited expression on healthy tissues (Clinical Trials GovNo.: NCT01716364). A 2 nd generation CAR-T cell product was tested in 4 patients with relapsed AML upon preconditioning with chemotherapy. Two patients achieved long-term remission, one patient a cytogenetic remission and the fourth patient showed a significant reduction of circulating blasts. The most notable finding from this study however was the lack of significant toxicity and the durable in vivo persistence of the CAR-T effectors [ 16]. LeY was the first antigen that was successfully implemented in CAR-T cell therapy approaches in AML (Table  1).
Table 1
The main evolution of CAR-Ts in AML (adapted from [ 22])
History of main types of CAR-Ts in AML
t: Lewis Y 2 ndG:CD28+CD3zeta
t: CD33
t: CD33
t: CD123
t: Lewis‑Y
2 ndG:CD28+CD3zeta
t: CD123
2 ndG:CD28+CD3zeta
t: CD44v6
2 ndG:CD28+CD3zeta
+suicide gene iC9
t: CD123
2 ndG:4-1BB+CD3zeta
t: CD123
2 ndG:CD28+CD3zeta+EGFRt
2 ndG:DAP10+CD3zeta
t: FRbeta
2 ndG:CD28+CD3zeta
Comparing the efficacy & safety of
CD33-CIK &
t: CD33
2 ndG:4-1BB+CD3zeta
t: CD33
t: CD123
2 ndG:4-1BB +TCR
t: CD33 – allogeneic
t: CD38
2 ndG:4-1BB +CD3zeta
t: CD33
2 ndG:CD28+OX40+
+suicide gene iC9
“GoCAR-T” CD123+iMC costimulation
t: CD33
2 ndG:CD28+CD3zeta+EGFRt
t: FLT3
2 ndG:4-1BB +CD3zeta
t: CD123 – DART
t: CD7
t: CLEC12A
t target, 2 nd G second generation, CIK cytokine induced killer, EBV-CTL Ebstein Barr Virus-cytotoxic lymphocyte, NKG2DL natural killer group 2D ligand, EGFRt a tag derived from epidermal growth factor receptor, is the antigen of the clinically available antibody cetuximab, DAP10 a type of natural adaptive protein, provides a costimulatory signal similar to that of CD28, ATRA all trans retinoic acid, a drug that up-regulates the expression of the target antigen, resulting in improved anti-leukemic activity, GoCAR-T a structure comprising a proliferation-deficient first generation CAR and a ligand-dependent activation switch (e.g. iMC) that efficiently eradicates CD123+AML cells when co-stimulated with systemic rimiducid administration, iMC inducible MyD88/CD40 is a ligand (rimiducid)-dependent co-stimulatory switch, DART dual-affinity re-targeting, TCR T cell receptor,  CLEC12A C-type lectin domain family 12 member A.
Another research group focused on CD38 as target. In this study the investigators could reveal another example of ATRA-enhanced cytotoxicity by using CD38-41-BB-CD3zeta CARs. Those results highlighted that ATRA may be an interesting combinatorial partner for CAR-T cells in AML [ 17]. ATRA is widely used for the treatment of acute promyelocytic leukemia (APL). It induces the differentiation of APL -cells, leading to suppression of proliferation capacity of these cells. Beside these effects, it has been reported that it may enhance CD38 expression on AML blasts [ 18].
As already mentioned above, CD33 is a highly interesting target as it is expressed in almost all AML patients as well as in AML stem cells. Because of these facts, CD33 is a promising CAR-T target. A trial by M. Kim et al. proposed an interesting but ambitious approach by CRISPR/Cas9-mediated removal of CD33 from normal hematopoietic stem and progenitor cells, thereby rendering these cells resistant to CD33-targeted CAR-T therapy [ 19]. Patients with minimal residual disease of AML first undergo conditioning before receiving allogeneic donor-derived CD33 KO HSPCs (CD33 knocked out hematopoietic stem and progenitor cells) followed by administration of CD33-directed CAR-T from the same donor.
Similar to CD33, the transmembrane alpha chain of the interkleukin‑3 receptor, CD123, is expressed on AML blasts to a high extent whereas it displays lower expression levels on healthy hematopoietic (stem) cells. Two clinical trials validated the effect and the safety profile (NCT02159495 and NCT02623582) of CD123-directed CAR-T. Concerns of a potential myeloablative effect by removing CD123 + cells could not be verified. One group even generated a 4 th generation CAR-T (antiCD123-CD28-CD137-CD27-CD3zeta-iCASP CAR = 4SCAR123) that is characterized by potent cytotoxicity against AML blast cells in vitro and then administered those CAR-Ts to a 47-year-old man with AML M2 (presented at ASH 2015 abstract #3778: First in man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia). Advanced protocols proposed to combine fully myeloablative CD123 CAR-Ts in conjunction with an adjacent allogeneic stem cell transplantation (SCT) to reduce the risk for AML relapse; however clinical data are not yet available.
FLT3 (Fms-like tyrosine kinase 3) also known as CD135 is a cytokine receptor belonging to the class III receptor tyrosine kinases. This gene belongs to the most commonly mutated genes in AML, characterized by internal tandem duplications of FLT3 (FLT3-ITD) reaching about 25% of AML cases. Targeting FLT3 by using a 2 nd generation CAR (4-1BB-CD3zeta) demonstrated potent anti-AML activity. Jetani et al. even demonstrated synergistic activity with a FLT3 inhibitor. Concomitant administration of crenolanib leads to an increase of surface expression of FLT3 specifically on FLT3-ITD + AML cells and consequently, enhanced recognition by FLT3-CARTs in vitro and in vivo. As anticipated, the myeloablative effect on healthy hematopoietic cells in vitro and in vivo required subsequent CAR-T depletion and allogeneic transplantation to reconstitute the hematopoietic system [ 20], again underscoring the current problem of limited AML-selectivity of the described CAR-T strategies.
Based on phase 1 data presented on the ASH 2017 and the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy in November 2018 Mustang Bio initiated a single-center, first in human phase 1 dose-escalation clinical trial (City of Hope; NCT02159495) evaluating the safety and anti-tumor activity of escalating doses of MB-102 (CD123 CAR-T) in patients with relapsed or refractory AML (cohort 1) and BPDCN (blastic plasmacytoid dendritic cell neoplasm, cohort 2). They demonstrated complete responses at low doses in BPDCN without dose-limiting toxicities. Dose escalation continues at City of Hope for both indications. In December 2018 Mustang Bio received Orphan Drug Designation for MB-102 for the treatment of BPDCN, a rare and incurable blood cancer with a median survival of less than 18 months and no standard of care. The great surprise came in July 2019 where FDA granted orphan drug designation to MB-102 for patients with acute myeloid leukemia. Subsequently, M. Litchman, president and CEO of Mustang Bio, announced to launch a phase I/II multicenter trial for patients with AML, BPDCN and high-risk MDS (myelodysplastic syndrome).
A different but promising cellular approach in the allogeneic transplant setting is illustrated by Chapuis et al. and published recently in Nature Medicine in 2019 [ 21]. The investigators isolated a high-affinity Wilms tumor antigen 1‑specific TCR (TCR C4) from HLA-A2 + regular donor repertoires, inserted TCR C4 into Epstein–Bar virus-specific donor CD8 + T cells (T TCR-C4) to minimize graft-versus-host disease risk and enhance transferred T cell survival. Those cells were prophylactically infused post HCT into 12 patients (NCT01640301). At a median of 44 months post infusion, relapse-free survival reached 100% compared to a concurrent group of 88 patients with a similar risk AML with a relapse-free survival of 54% ( p = 0.002). The authors finally stated that these long-term persisting cells maintained TCR CR4 expression by staying polyclonal. This strategy appears prospective for preventing AML recurrence in individuals at increased risk of post-HCT relapse. It represents a different strategy beside CAR-Ts but highlights a sophisticated cellular treatment approach.
Take Home Message
Despite various approvals during the last 2 years, AML still represents a malignant disease with a dismal prognosis. This is reflected by many cases of primary or secondary refractory AML patients leading to relapse, even upon allogeneic stem cell transplantation. Even though CAR-T cell therapy is highly effective in NHL and ALL, CAR-T therapies in AML are limited by the insufficient selectivity of the currently approached CAR-T targets. Despite that, preliminary data are at least in part promising in terms of their anti-AML efficacy, but the potential elimination of healthy hematopoietic stem cells may lead to long-term myelosuppression requiring rescue allogeneic SCT. This currently limits the clinical development of this treatment strategy in AML and still claims for new investigational approaches.

Conflict of interest

J. D. Rudzki declares that he has received honoraria and speaker’s fee from BMS, Roche, MSD, AstraZeneca, Amgen, Gilead-kite, Novartis and served as advisor for BMS, Roche, MSD, AstraZeneca, Amgen, Gilead-kite, Novartis and BMS/Celgene. D. Wolf declares that he has received honoraria and speaker’s fee from Novartis, Gilead, BMS/Celgene, served as advisor for Novartis, Gilead, BMS/Celgene and GEMoaB and receives research funding from Novartis and BMS/Celgene.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020 Zur Ausgabe